Shattuck Labs Inc (STTK) Stock Price, Quote & News

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 900 4690

Website: www.shattucklabs.com

Address:

500 West 5th Street, Suite 1200, Austin, United States

PepCF Sep. 12 at 5:51 AM

$STTK

0 · Reply

Bretomo Sep. 11 at 3:22 PM

$STTK I love this stock

0 · Reply

algo888 Sep. 10 at 2:18 PM

$STTK move profits to (EQ) up 7%

0 · Reply

Alidrisi Sep. 10 at 11:26 AM

$STTK

0 · Reply

StockScanners Sep. 10 at 2:08 AM

$STTK reached 2.04

0 · Reply

DogDayDreaming Sep. 9 at 6:04 PM

$STTK Order book right now signaling a stock still under accumulation (10x ask vs. bid as I type, as one example) STTK SHATTUCK LABS INC COM $2.02+0.14 (+7.45%) Bid x Size $2.01 x 2,300 Ask x Size $2.02 x 24,200 Real Time Equity Quote: Sep 9, 2025, 2:02 PM ET

2 · Reply

kubota2323 Sep. 9 at 4:57 PM

$STTK

0 · Reply

Bswartz95 Sep. 9 at 4:52 PM

$STTK next stop $3.

0 · Reply

JamezMtnDoU Sep. 9 at 4:03 PM

$STTK let’s break $1.95!!

0 · Reply

Howard678 Sep. 9 at 3:54 PM

$STTK Lets break $1.95 and go to $2.25 and beyond 🎉🎉

0 · Reply

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Aug 21, 2025, 10:17 AM EDT - 21 days ago

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Aug 14, 2025, 6:30 AM EDT - 4 weeks ago

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 5, 2025, 6:30 AM EDT - 5 weeks ago

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Jul 2, 2025, 7:00 AM EDT - 2 months ago

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

May 1, 2025, 4:20 PM EDT - 4 months ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 2, 2025, 5:00 PM EDT - 5 months ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Feb 20, 2025, 9:00 AM EST - 7 months ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 7 months ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 4, 2025, 7:00 AM EST - 7 months ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Jan 6, 2025, 4:59 PM EST - 8 months ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 9 months ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Oct 29, 2024, 10:00 AM EDT - 11 months ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Oct 28, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

Oct 27, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

Oct 23, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

Oct 22, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

Oct 21, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

Oct 20, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

Oct 16, 2024, 10:00 AM EDT - 11 months ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Oct 15, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

Oct 14, 2024, 6:00 PM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

Oct 1, 2024, 12:23 PM EDT - 1 year ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 6:30 AM EDT - 1 year ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Jul 30, 2024, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 6, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My

May 14, 2024, 4:15 PM EDT - 1 year ago

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E

May 2, 2024, 7:05 AM EDT - 1 year ago

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Mar 4, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.

Feb 29, 2024, 4:05 PM EST - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Feb 26, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Participation in Upcoming March Conferences

Feb 14, 2024, 5:06 AM EST - 1 year ago

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

Feb 13, 2024, 6:00 AM EST - 1 year ago

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

Jan 8, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Jan 4, 2024, 4:05 PM EST - 1 year ago

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

PepCF Sep. 12 at 5:51 AM

$STTK

0 · Reply

Bretomo Sep. 11 at 3:22 PM

$STTK I love this stock

0 · Reply

algo888 Sep. 10 at 2:18 PM

$STTK move profits to (EQ) up 7%

0 · Reply

Alidrisi Sep. 10 at 11:26 AM

$STTK

0 · Reply

StockScanners Sep. 10 at 2:08 AM

$STTK reached 2.04

0 · Reply

DogDayDreaming Sep. 9 at 6:04 PM

2 · Reply

kubota2323 Sep. 9 at 4:57 PM

$STTK

0 · Reply

Bswartz95 Sep. 9 at 4:52 PM

$STTK next stop $3.

0 · Reply

JamezMtnDoU Sep. 9 at 4:03 PM

$STTK let’s break $1.95!!

0 · Reply

Howard678 Sep. 9 at 3:54 PM

$STTK Lets break $1.95 and go to $2.25 and beyond 🎉🎉

0 · Reply

PepCF Sep. 9 at 3:16 PM

$STTK

0 · Reply

Ga0Ga Sep. 9 at 5:39 AM

$STTK ?

0 · Reply

StockScanners Sep. 9 at 4:21 AM

$STTK reached 1.95

0 · Reply

ThanosInfinite Sep. 9 at 2:30 AM

$PAPL $HOUR $SNTG $QMMM $STTK Make sure you have MSS as well. Ticker MSS Should be on everyone's top list💎💎 MSS has $3 fair value, No dilution, cash flow positive , almost zero borrow. This is going to be next squeeze in this hot market. Don't miss out bulls. 🚨🚨

0 · Reply

SadyK189 Sep. 9 at 12:06 AM

Top Stocks to watch tomorrow 2 / 2: $PAPL $HOUR $SNTG $QMMM $STTK PAPL remained in consolidation mode today. Looking good on daily chart. Key support at 5.60 - 5.90. Next key level to test is 8.10 - 8.45. Currently at 6.92 SNTG: Looking good on 4hours chart. Key support at 4.3 - 4.60. Next key level to test is 6.80 - 7.20. Currently at 5.81 QMMM: Initially alerted at 3.69. Still trending nicely on daily chart. Key support at 9.30 - 9.75. Next key level to test is 12.40 - 12.80. STTK is moving slowly and steadily but nicely on daily chart. Key support at 1.40 - 1.55. Next key level to test is 2.30 - 2.50. It may take sometime though HOUR: Looking good on daily chart. Key support at 4.20 - 4.50. Next key level to test is 6.15 - 6.55. Currently at 5.38

0 · Reply

Pirlo247 Sep. 8 at 7:50 PM

$STTK Shattuck Labs (STTK) shows stronger characteristics for a potential short squeeze: • Very low days-to-cover (~0.3) — increases urgency for shorts to cover quickly if buying starts. • Moderate short float (~4%) and a borrow rate of ~5.2% add pressure. • This combination makes STTK more prone to rapid upward moves under the right catalysts.

0 · Reply

kubota2323 Sep. 8 at 6:38 PM

$STTK $BLNE adding $ASST

0 · Reply

DogDayDreaming Sep. 8 at 5:26 PM

$STTK Wedbush Upgrade:

0 · Reply

DARKP00L Sep. 8 at 5:00 PM

$STTK 12:06 on Sep. 08 2025 Shattuck Labs shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced $4 price target. #tradeideas

0 · Reply

prismmarketview Sep. 8 at 4:27 PM

Prism Midday Movers: Tech and Energy Shine While Biotechs Slide Planet Labs ( $PL) up 36.2% Shares soared more than 35% today, hitting a fresh 52-week high after reporting record Q2 revenue of $73.4M (+20% YoY). QuantumScape Corp ( $QS) up 26% Shares surged 26% after showcasing its QSE-5 solid-state battery in a Ducati motorcycle at IAA Mobility. The demo, backed by Volkswagen’s PowerCo and Ducati, highlighted faster charging, higher energy density, and stronger safety. Other PRISM Mid-Day Movers: Shattuck Labs, Inc. ( $STTK) Up 19.9% Palatin Technologies, Inc. ( $PTN) Down 44% TFF Pharmaceuticals ( $TFFP) Down 60% https://prismmarketview.com/prism-midday-movers-tech-and-energy-shine-while-biotechs-slide/

0 · Reply

JamezMtnDoU Sep. 8 at 3:18 PM

$STTK in$1.90. Holding this whole week!!

0 · Reply

Atrader999 Sep. 8 at 3:11 PM

$STTK price target this week?

0 · Reply

Market Cap	83.83M
Revenue (ttm)	5.72M
Net Income (ttm)	-75.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,318.36%
Debt to Equity Ratio	0.00

Volume	531,000
Avg Vol	2,743,906
Day's Range	N/A - N/A
Shares Out	47.90M
Stochastic %K	94%
Beta	1.64
Analysts	Sell
Price Target	$2.31